- Home
- TYG vs KALV Comparison
TYG vs KALV Comparison
Compare TYG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYG | KALV |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TYG | KALV |
|---|---|---|
| Price | $43.82 | $26.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 167.8K | ★ 3.9M |
| Earning Date | 05-04-2026 | 07-09-2026 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $40.28 | $9.83 |
| 52 Week High | $51.18 | $26.85 |
Technical Indicators
Market Signals| Indicator | TYG | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 30.12 | 74.29 |
| Support Level | $42.34 | $14.22 |
| Resistance Level | $43.96 | $26.85 |
| Average True Range (ATR) | 0.79 | 0.06 |
| MACD | -0.28 | -0.28 |
| Stochastic Oscillator | 2.03 | 76.47 |
Price Performance
Historical ComparisonAbout TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.